- SEK1.45bn
- SEK1.36bn
- SEK313.35m
Brief: Paxman Q3 Revenue SEK 64.8 Million
Brief: Paxman Gets Initial Order Under Contract For Provision Of Scalp Cooling Systems
Brief: Paxman Q2 Revenue SEK 63.4 Million
Brief: Paxman Signs Contract With U.S. Department Of Veterans Affairs
Brief: Paxman Q1 Revenue SEK 58.6 Million
Brief: Paxman Q4 Revenue SEK 55.6 Million
Brief: Paxman Board Member Sells 100,000 Shares At SEK 31 Per Share
Brief: Paxman Q3 EBITDA SEK 13 Million
Brief: Paxman: Palmetto GBA Approves First Local Coverage Determination For Scalp Cooling Therapy
Brief: Paxman Q1 EBITDA at SEK 2.7 Million
Brief: Paxman Q4 EBITDA Rises To SEK 12.8 Mln
Brief: Paxman Q4 EBITDA at SEK 12.8 Million
Brief: Paxman Scalp Cooling System Receives EU MDR Certification
Brief: Paxman Q3 EBITDA Turns To Profit At SEK 5.6 Million
Brief: Paxman Limb Cryocompression System To Be Used In Swog Cancer Research Network Study Testing
Brief: Paxman Q2 EBITDA Swings To Profit SEK 0.3 Million
Brief: Paxman Q1 Net Loss Widens To SEK 6.2 Mln
Brief: Paxman Signs First Contract Under New Business Model
Brief: Paxman Signs LoI To Jointly Develop Chinese Market For Paxman Scalp Cooler